This Week in Obstetrics & Gynecology — Oct 1, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Obstetrics and Gynecology. This week we're covering 10 notable papers spanning early pregnancy risk stratification and pre-eclampsia, the conduct of labour and birth, and reproductive medicine from endometrial scratching to a decade of uterus transplantation. Let's dive in.

We start with a cluster of papers arguing that the centre of gravity in antenatal care is shifting towards the first trimester. In a Policy Forum in PLOS Medicine, Magee and colleagues revisit the inverted pyramid of care, the idea first floated in 2011 that structured risk assessment belongs early in pregnancy rather than in an accelerating series of late visits [3]. Their updated position is that screening can now be contingent, with a defined subgroup pulled back for re-screening in mid or late pregnancy, and that maternal conditions like pre-eclampsia, intrinsic fetal conditions such as chromosomal abnormalities, and uteroplacental problems including placenta accreta spectrum can each be predicted or identified earlier than they traditionally have been. This is advocacy rather than trial evidence, and the authors are explicit that they are proposing optimal screening timepoints and risk-stratified pathways, including a future role for artificial intelligence assisted tools, not reporting an outcome. A secondary analysis in Ultrasound in Obstetrics and Gynecology puts numbers on what happens after that early risk assessment. Lin and colleagues analysed a stepped-wedge cluster randomised trial across 18 units in ten regions of Asia, following 2,919 singleton pregnancies flagged as high risk for preterm pre-eclampsia by the first-trimester Fetal Medicine Foundation triple test and treated with low-dose aspirin [4]. Despite prophylaxis, just under one in ten of these women developed pre-eclampsia and roughly one in twenty-seven developed preterm pre-eclampsia. The residual risk was not evenly distributed: chronic hypertension and a raised mean arterial pressure multiple of the median each independently predicted preterm disease, and the gradient across estimated risk categories was steep, with women in the highest band, a risk of one in two to one in five, carrying around sixteen times the odds of preterm pre-eclampsia compared with those at the one in fifty-one to one in one hundred threshold. Time-to-event analysis showed the same pattern for earlier delivery with pre-eclampsia. The practical message the authors draw is that a binary high-risk label conceals a wide spectrum, and that stratifying within the high-risk group may identify those for whom aspirin alone is not enough. This is a secondary analysis, so it is hypothesis-generating for how screening thresholds might be refined rather than a basis for changing prophylaxis. Complementing that, a Scientific Impact Paper in BJOG from Foo and colleagues reviews maternal cardiovascular function in pre-eclampsia [5]. Their synthesis describes two distinct haemodynamic phenotypes: women with low cardiac output and high vascular resistance who tend towards early-onset disease and growth-restricted infants, and women with a higher circulating volume who tend towards late-onset disease with normally grown or larger babies. Because non-invasive measurement of cardiac output and vascular resistance is now feasible, the authors argue this opens the door to phenotype-directed antihypertensive choice and personalised surveillance. It is a mechanistic and consensus document rather than randomised evidence that tailoring drugs to haemodynamics improves outcomes, and that trial has not been done.

Turning to labour and birth, three papers address what we actually do in the delivery room. In the American Journal of Obstetrics and Gynecology, Balayla and colleagues report a systematic review and meta-analysis of transcervical balloon ripening and uterine rupture during trial of labour after caesarean, pooling eighteen non-randomised studies and two randomised trials, some twenty-eight thousand observations including over five and a half thousand balloon exposures [1]. Compared with prostaglandin induction, a balloon-based strategy was associated with less than half the odds of complete uterine rupture, an absolute difference of roughly nineteen fewer ruptures per thousand. Against oxytocin alone and against spontaneous labour, no difference in complete rupture was detected. There is a counterweight, though: dehiscence was reported roughly twice as often after balloon-based induction. Two important caveats come from the authors themselves. Because amniotomy, oxytocin, or both followed catheter placement in nearly every protocol, the exposure is a balloon-based induction strategy and not the catheter in isolation, and certainty of evidence was rated very low throughout. Their conclusion is that mechanical ripening remains reasonable in carefully selected candidates when induction is indicated, with counselling, continuous monitoring, and immediate access to emergency caesarean. Also in BJOG, Bewley and colleagues update the Scientific Impact Paper on care of the newborn and cord during the third stage [2]. The headline from their review is that accumulating evidence leaves very little justification for immediate cord clamping at any gestation, with reductions in neonatal harm and death when placental transfusion is allowed to proceed, and the benefit most pronounced in preterm infants. They estimate that a term baby receives around thirty percent of its total blood volume by placental transfer, and they make two specific points that cut against common habit: the decision to clamp should follow observation of the baby's heart rate and breathing rather than a predefined interval, and palpable cord pulsation does not reflect net blood flow and so is not a useful guide to timing. Staying with intrapartum care, Obstetrics and Gynecology publishes a systematic review by Viswanathan and colleagues covering twelve randomised trials and eighteen non-randomised studies of doula support in the United States [7]. At moderate certainty, doula support was likely associated with lower rates of preterm birth and caesarean delivery, improved birth experiences, and greater attendance at the postpartum visit. A longer list of outcomes, including breastfeeding initiation, spontaneous vaginal birth, vaginal birth after caesarean and reduced epidural use, sat at low certainty, and doula support may not reduce hypertensive disorders, maternal readmissions or neonatal intensive care admissions. Only one study was at low risk of bias and nineteen were at high risk, so the signal is consistent but the evidence base is fragile; notably, among studies conducted entirely in populations at risk of disparities, four of five reported at least some benefit.

On the reproductive medicine side, the week brings one clear negative trial and two state-of-the-field reviews. In Human Reproduction, the SCRaTCH-OFO trial led by Preesman randomised 593 patients with unexplained infertility and a good prognosis for natural conception across 31 Dutch hospitals to endometrial scratching or no intervention [8]. Cumulative live birth was 64 percent with scratching and 57 percent without, a difference that was not statistically significant, with no significant difference in time to pregnancy or in clinical pregnancy, miscarriage or ectopic rates, and no severe complications. The trial fell short of its planned sample size because of slower than expected enrolment, so it is underpowered rather than definitively null, but it provides no support for scratching in this good-prognosis group. Obstetrics and Gynecology also reports ten years of uterus transplantation in the United States, a prospective cohort from all four active programmes assembled by O'Neill and colleagues covering sixty transplants, most for Mayer-Rokitansky-Küster-Hauser syndrome and seventy percent from living donors [6]. Seventy percent of recipients had achieved at least one live birth or an ongoing pregnancy, and nine had two live births. There were no deaths or life-threatening complications, but reoperation was needed in just over a quarter of recipients, including graft loss from vascular thrombosis, and in about one in seven living donors, including ureteral injury. Of the forty-eight neonates, median gestational age was about thirty-seven weeks and well over half were preterm. At three-year follow-up of twenty-nine children, two had been diagnosed with autism, with no other diagnoses or growth disorders. These are aggregate registry-style data, but they are the contemporary reference point for counselling on absolute uterine factor infertility. Alongside this, a second-edition Scientific Impact Paper in BJOG from Anderson and colleagues on elective egg freezing emphasises that success is strongly age-dependent, with substantially better outcomes below age thirty-five, while most women currently freezing are already in their late thirties, and it raises concerns about marketing accuracy in a largely private-sector market [10]. Finally, in Gynecologic Oncology, Suh-Burgmann and colleagues examined germline testing in a community-based cohort of over ten thousand women with endometrial cancer [9]. Only about one in seven had been tested, and the estimated prevalence of pathogenic germline variants in the overall population was close to twelve percent, including under two percent with Lynch syndrome and nearly five percent with homologous recombination deficiency related variants. Testing at diagnosis captured three of every four positive cases, nearly all the Lynch variants but only about half of the homologous recombination deficiency related ones, suggesting the timing of testing systematically shapes what gets found.

If you only have time for one paper this week, make it the balloon ripening meta-analysis in the American Journal of Obstetrics and Gynecology [1]. It addresses one of the most common counselling dilemmas in obstetrics, induction in a woman with a previous caesarean, and while the very low certainty means it settles nothing definitively, it reframes the question away from the catheter itself and towards the whole induction strategy that follows it.

Here is what this week's evidence adds up to in Obstetrics and Gynecology. First, early pregnancy risk stratification is maturing from a concept into a graded one, with the Asian aspirin analysis showing that women labelled high risk by first-trimester screening carry very different residual risks depending on chronic hypertension, mean arterial pressure and the magnitude of their estimated risk, though this comes from secondary analysis and has not been tested prospectively. Second, for trial of labour after caesarean, pooled observational data do not show an excess of complete uterine rupture with balloon-based induction compared with spontaneous labour or oxytocin, and show fewer ruptures than with prostaglandins, with the caveat of more reported dehiscence and uniformly very low certainty. Third, the cord clamping review concludes that immediate clamping has little justification at any gestation and that timing is better guided by the infant's own transition than by a clock or by cord pulsation. Fourth, doula support shows a consistent association with lower preterm birth and caesarean rates at moderate certainty, from a literature dominated by studies at high risk of bias. And fifth, endometrial scratching in good-prognosis unexplained infertility did not significantly improve live birth in a multicentre randomised trial that was somewhat underpowered, while germline testing in endometrial cancer remains uncommon in community practice and the timing of testing determines which variants are found.

That's your roundup for This Week in Obstetrics and Gynecology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if it saves you time, a quick rating in your podcast app helps other physicians find the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.